Literature DB >> 1673034

The challenge of long-acting beta-adrenoceptor agonists.

K F Rabe1, K F Chung.   

Abstract

Mesh：

Substances：

Year:  1991        PMID： 1673034     DOI： 10.1016/s0954-6111(06)80203-9

Source DB:  PubMed          Journal:  Respir Med        ISSN： 0954-6111            Impact factor:   3.415


× No keyword cloud information.
  6 in total

Review 1.  Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Authors:  L P Boulet
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 2.  Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.

Authors:  R N Brogden; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 3.  Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists.

Authors:  A Lindén; K F Rabe; C G Löfdahl
Journal:  Lung       Date:  1996       Impact factor: 2.584

4.  Formoterol, fenoterol, and salbutamol as partial agonists for relaxation of maximally contracted guinea pig tracheae: comparison of relaxation with receptor binding.

Authors:  H Lemoine; C Overlack; A Köhl; H Worth; D Reinhardt
Journal:  Lung       Date:  1992       Impact factor: 2.584

Review 5.  [Long-acting beta(2)-adrenoceptor agonists for asthma and COPD].

Authors:  K F Rabe; D Ukena; H Magnussen
Journal:  Med Klin (Munich)       Date:  1997-12

6.  Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours.

Authors:  D Nowak; R Jörres; K F Rabe; M Lüthke; J Wiessmann; H Magnussen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.